These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34512672)

  • 21. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
    Emu B; Sinclair E; Hatano H; Ferre A; Shacklett B; Martin JN; McCune JM; Deeks SG
    J Virol; 2008 Jun; 82(11):5398-407. PubMed ID: 18353945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers.
    Tjiam MC; Morshidi MA; Sariputra L; Martin JN; Deeks SG; Tan DBA; Lee S; Fernandez S; French MA
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):e90-e92. PubMed ID: 28604502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.
    Lambotte O; Ferrari G; Moog C; Yates NL; Liao HX; Parks RJ; Hicks CB; Owzar K; Tomaras GD; Montefiori DC; Haynes BF; Delfraissy JF
    AIDS; 2009 May; 23(8):897-906. PubMed ID: 19414990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.
    Moyo S; Gaseitsiwe S; Mohammed T; Pretorius Holme M; Wang R; Kotokwe KP; Boleo C; Mupfumi L; Yankinda EK; Chakalisa U; van Widenfelt E; Gaolathe T; Mmalane MO; Dryden-Peterson S; Mine M; Lebelonyane R; Bennett K; Leidner J; Wirth KE; Tchetgen Tchetgen E; Powis K; Moore J; Clarke WA; Lockman S; Makhema JM; Essex M; Novitsky V
    PLoS One; 2018; 13(10):e0204840. PubMed ID: 30356287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
    Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
    J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural control of HIV infection in young women in South Africa: HPTN 068.
    Sivay MV; Fogel JM; Wang J; Zhang Y; Piwowar-Manning E; Clarke W; Breaud A; Blankson J; Hamilton EL; Kahn K; Selin A; Gomez-Olive FX; MacPhail C; Hughes JP; Pettifor A; Eshleman SH
    HIV Clin Trials; 2018 Oct; 19(5):202-208. PubMed ID: 30522410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-Reactivity Between Influenza Matrix- and HIV-1 P17-Specific CTL-A Large Cohort Study.
    Hückelhoven AG; Etschel JK; Bergmann S; Zitzelsberger K; Mueller-Schmucker SM; Harrer EG; Harrer T
    J Acquir Immune Defic Syndr; 2015 Aug; 69(5):528-35. PubMed ID: 25900164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.
    Van Gulck E; Bracke L; Heyndrickx L; Coppens S; Atkinson D; Merlin C; Pasternak A; Florence E; Vanham G
    PLoS One; 2012; 7(5):e37792. PubMed ID: 22666392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
    Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.
    Zhou M; Meyer T; Koch S; Koch J; von Briesen H; Benito JM; Soriano V; Haberl A; Bickel M; Dübel S; Hust M; Dietrich U
    Eur J Immunol; 2013 Feb; 43(2):499-509. PubMed ID: 23180650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease Progression in HIV-1-Infected Viremic Controllers.
    Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rate and predictors of progression in elite and viremic HIV-1 controllers.
    Leon A; Perez I; Ruiz-Mateos E; Benito JM; Leal M; Lopez-Galindez C; Rallon N; Alcami J; Lopez-Aldeguer J; Viciana P; Rodriguez C; Grau E; Iribarren J; Gatell JM; Garcia F;
    AIDS; 2016 May; 30(8):1209-20. PubMed ID: 26854807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra-host evolutionary rates in HIV-1C env and gag during primary infection.
    Novitsky V; Wang R; Rossenkhan R; Moyo S; Essex M
    Infect Genet Evol; 2013 Oct; 19():361-8. PubMed ID: 23523818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera.
    Liu X; Ota A; Watanabe M; Ueda S; Saitoh A; Shinagawa H; Nakata A; Kurimura T; Wang X; Zhao Y
    Microbiol Immunol; 1995; 39(10):775-85. PubMed ID: 8577268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.
    Buratti E; Tisminetzky SG; D'Agaro P; Baralle FE
    J Virol; 1997 Mar; 71(3):2457-62. PubMed ID: 9032383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.
    Keating SM; Pilcher CD; Jain V; Lebedeva M; Hampton D; Abdel-Mohsen M; Deng X; Murphy G; Welte A; Facente SN; Hecht F; Deeks SG; Pillai SK; Busch MP
    J Infect Dis; 2017 Jul; 216(1):72-81. PubMed ID: 28498985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
    Gonzalo-Gil E; Ikediobi U; Sutton RE
    Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.
    Egaña-Gorroño L; Escribà T; Boulanger N; Guardo AC; León A; Bargalló ME; Garcia F; Gatell JM; Plana M; Arnedo M;
    PLoS One; 2014; 9(9):e106360. PubMed ID: 25225963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.